谷氨酰胺酶 (Glutaminase) 是谷氨酰胺代谢的起始酶,在细胞内催化谷氨酰胺水解为谷氨酸。谷氨酰胺酶在癌细胞代谢、生长和增殖中起着关键作用。在哺乳动物细胞中,有两个旁系同源物GLS基因,GLS1(或GLS)和GLS2。GLS1编码两种可变剪接的同工酶:肾谷氨酰胺酶(KGA)和谷氨酰胺酶C(GAC)。GLS2也编码两种同工酶:肝谷氨酰胺酶(LGA)和谷氨酰胺酶B。
GLS1在各种组织中普遍表达,其表达可由致癌基因MYC诱导。GLS1 在各种类型的癌症中经常被激活和/或过度表达,包括肝细胞癌 (HCC)。据报道,GLS1 可促进包括 HCC 在内的各种癌症的肿瘤发生,这主要归因于其谷氨酰胺酶活性和促进谷氨酰胺代谢的作用。GLS 已成为多种癌症类型中的关键酶。GLS2 酶活性升高也与体外和体内肿瘤细胞生长有关。N-Myc 激活 GLS2 以促进 MYCN 扩增的神经母细胞瘤细胞中谷氨酰胺转化为谷氨酸。GLS2 功能的消除会严重抑制谷氨酰胺分解,并显著降低体外和体内细胞增殖和存活率。然而,GLS2 作为肿瘤抑制因子的作用存在争议。独立于 GLS2 的酶活性通过 p53 或 p63 上调,并发挥肿瘤抑制因子的作用。
Glutaminase is the initial enzyme in glutamine metabolism, which catalyzes the hydrolysis of glutamine to glutamate in cells. Glutaminase plays a key role in cancer cell metabolism, growth, and proliferation. In mammalian cells, there are two paralogous GLS genes, GLS1 (or GLS) and GLS2. GLS1 encodes two alternatively spliced isozymes: kidney glutaminase (KGA) and glutaminase C (GAC). GLS2 also encodes two isozymes: liver glutaminase (LGA) and glutaminase B.
GLS1 is ubiquitously expressed in various tissues, and its expression can be induced by the oncogene MYC. GLS1 is frequently activated and/or overexpressed in various types of cancer, including hepatocellular carcinoma (HCC). GLS1 has been reported to promote tumorigenesis in different types of cancer, including HCC, which is mainly attributable to its glutaminase activity and role in promoting glutamine metabolism. GLS has emerged as a critical enzyme in a number of cancer types. Elevated GLS2 enzymatic activity has also been correlated with tumor cell growth in vitro and in vivo. N-Myc activates GLS2 to promote conversion of glutamine to glutamate in MYCN-amplified neuroblastoma cells. Abrogation of GLS2 function profoundly inhibits glutaminolysis and dramatically decreases cell proliferation and survival in vitro and in vivo. However, there is controversy over the role of GLS2 as a tumor suppressor. Enzymatic activity independent of GLS2 is up-regulated via p53 or p63 and plays a role of tumor suppressor.
2-Amino-2-(p-tolyl)acetic acid 可用于优化叠氮骨架,是 1,3,4-噻二唑类化合物的中间体,而 1,3,4-噻二唑类化合物具有潜在抗癌活性并抑制谷氨酰胺酶。
6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) 是一种谷氨酰胺拮抗剂,可不可逆地抑制谷氨酰胺的分解,具有良好的抗癌活性(尤其是胰腺癌),能降低肿瘤细胞的自我更新潜力和转移能力,并具有抗菌和抗病毒活性。
6-Diazo-5-oxo-L-nor-Leucine (Standard) 是 6-Diazo-5-oxo-L-nor-Leucine 的分析标准品,本产品用于研究及分析应用;6-Diazo-5-oxo-L-nor-Leucine (L-6-Diazo-5-oxonorleucine; DON) 是一种谷氨酰胺拮抗剂,能不可逆地抑制谷氨酰胺的分解作用,具有较好的抗癌活性(尤其是胰腺癌),能降低肿瘤细胞的自我更新潜力和转移能力。
AA9 是一种有效的 Transglutaminase 2 (TG2) 抑制剂,对 HIF 介导的 MDA-MB-231 细胞缺氧具有较强的影响。
Antiproliferative agent-73(Compound 7)是一种抗增殖剂,能显著抑制人类癌细胞增殖并具有优异的细胞毒性,对 HepG2、MCF-7、HCT-116 和 WI38 细胞的 IC50 分别为 15.20 μM、18.18 μM、20.20 μM 和 13.23 μM,具有强效抗癌活性,可用于乳腺癌、结直肠癌和肝癌等癌症研究。
Barbinervic acid 是一种谷氨酰胺酶 (glutaminase) 抑制剂,其 IC50 为 14 μM,可用于神经退行性疾病的研究。
BJJF078 是一种氨基哌啶衍生物,是重组人和小鼠谷氨酰胺转氨酶 (TG2) 活性的有效抑制剂,IC50 值分别为 41 和 54 nM,同时也抑制密切相关的 TG1 酶(IC50 为 0.16 μM),可用于多发性硬化症 (MS) 研究。
BPTES (Standard) 是 BPTES 的分析标准品,用于研究及分析应用,作为选择性谷氨酰胺酶变构抑制剂,其 IC50 为 0.16 μM。